Encompass Capital Advisors LLC
-2.56%
3M Return
$2.210
+0.149 (+6.76%)At close
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.
Given the current price of 2.65 and an RSI of 28.386, ASPI is currently oversold, indicating potential for a rebound. However, the stock has experienced a significant decline of 80.11% over the past year, and the forward P/E ratio is 54.35, suggesting high valuation concerns. The main risk is the negative net income of -33,585,000 reported for Q2 2026, which raises questions about profitability.

Investigation into ASP Isotopes Shareholder Rights

ASP Isotopes Inc. Hosts Inaugural Capital Markets Day in London

Schedule Released for 95th Emerging Growth Conference

ASP Isotopes Reports Operational Progress Ahead of Q2 Results

Senators Demand Investigation into Trump Family Mineral Deals
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets. It operates in the Healthcare sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).
Given the current price of 2.65 and an RSI of 28.386, ASPI is currently oversold, indicating potential for a rebound. However, the stock has experienced a significant decline of 80.11% over the past year, and the forward P/E ratio is 54.35, suggesting high valuation concerns. The main risk is the negative net income of -33,585,000 reported for Q2 2026, which raises questions about profitability.

$ASPI Finally a decent weekly candle, a hammer candle at that horrible channel support.
Show more

$ASPI Every year, I tend to have one weak spot in my portfolio. This year, it’s this one. What a disappointment! Monthly chart.
Show more
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.